Association analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levels by Spracklen, Cassandra N. et al.
A S S O C I A T I O N S T U D I E S A R T I C L E
Association analyses of East Asian individuals and
trans-ancestry analyses with European individuals
reveal new loci associated with cholesterol and
triglyceride levels
Cassandra N. Spracklen1,†, Peng Chen2,3,†, Young Jin Kim4,†, Xu Wang5,†,
Hui Cai6,†, Shengxu Li7,†, Jirong Long6,†, Ying Wu1,†, Ya Xing Wang8,†,
Fumihiko Takeuchi9,†, Jer-Yuarn Wu10,11,†, Keum-Ji Jung12,†, Cheng Hu13,†,
Koichi Akiyama9,†, Yonghong Zhang14,†, Sanghoon Moon4,†,
Todd A. Johnson15,†, Huaixing Li16,†, Rajkumar Dorajoo17,†, Meian He18,†,
Maren E. Cannon1, Tamara S. Roman1, Elias Salfati19, Keng-Hung Lin20,
Xiuqing Guo21, Wayne H.H. Sheu22,23,24,25, Devin Absher26, Linda S. Adair27,
Themistocles L. Assimes19, Tin Aung28,29,30, Qiuyin Cai6, Li-Ching Chang10,
Chien-Hsiun Chen10,11, Li-Hsin Chien31, Lee-Ming Chuang32,33,34,
Shu-Chun Chuang31, Shufa Du27,35, Qiao Fan28, Cathy S.J. Fann10,
Alan B. Feranil36,37, Yechiel Friedlander38, Penny Gordon-Larsen27,35,
Dongfeng Gu39, Lixuan Gui18, Zhirong Guo14, Chew-Kiat Heng40,41,
James Hixson42, Xuhong Hou13, Chao Agnes Hsiung31, Yao Hu16,
Mi Yeong Hwang4, Chii-Min Hwu23,43, Masato Isono9,
Jyh-Ming Jimmy Juang33,44, Chiea-Chuen Khor17,45, Yun Kyoung Kim4,
Woon-Puay Koh2,29, Michiaki Kubo46, I-Te Lee22,23,47, Sun-Ju Lee12,
Wen-Jane Lee48,49, Kae-Woei Liang23,50,51, Blanche Lim28, Sing-Hui Lim28,
Jianjun Liu2,17,52, Toru Nabika53, Wen-Harn Pan10, Hao Peng14, Thomas
Quertermous19, Charumathi Sabanayagam28,29, Kevin Sandow21, Jinxiu Shi54,
Liang Sun16, Pok Chien Tan28, Shu-Pei Tan28, Kent D. Taylor21, Yik-Ying
Teo2,5,17,55,56, Sue-Anne Toh52, Tatsuhiko Tsunoda15,57, Rob M. van Dam2,
Aili Wang14, Feijie Wang16, Jie Wang13, Wen Bin Wei58, Yong-Bing Xiang59,
†
These authors contributed equally to this work.
Received: October 14, 2016. Revised: January 27, 2017. Accepted: February 16, 2017
VC The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
1770
Human Molecular Genetics, 2017, Vol. 26, No. 9 1770–1784
doi: 10.1093/hmg/ddx062
Advance Access Publication Date: 21 February 2017
Association Studies Article
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/26/9/1770/3039197 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
Jie Yao21, Jian-Min Yuan60,61, Rong Zhang13, Wanting Zhao28,29,
Yii-Der Ida Chen21, Stephen S. Rich62, Jerome I. Rotter21,
Tzung-Dau Wang33,44, Tangchun Wu18,†, Xu Lin16,†, Bok-Ghee Han63,†,
Toshihiro Tanaka64,65,†, Yoon Shin Cho66,†, Tomohiro Katsuya67,†,
Weiping Jia13,†, Sun-Ha Jee12,†, Yuan-Tsong Chen10,†, Norihiro Kato9,†,
Jost B. Jonas8,68,†, Ching-Yu Cheng28,29,30,†, Xiao-Ou Shu6,†, Jiang He7,†,
Wei Zheng6,†, Tien-Yin Wong28,29,30,†, Wei Huang54,†, Bong-Jo Kim4,†,
E-Shyong Tai2,29,52,†, Karen L. Mohlke1,† and Xueling Sim2,*,†
1Department of Genetics, University of North Carolina, Chapel Hill, NC, USA, 2Saw Swee Hock School of Public
Health, National University Health System, National University of Singapore, Singapore, Singapore, 3Key
Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China, 4Division of Structural
and Functional Genomics, Center for Genome Science, Korean National Institute of Health, Osong,
Chungchungbuk-do, South Korea, 5Life Sciences Institute, National University of Singapore, Singapore,
Singapore, 6Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt
University Medical Center, Nashville, Tennessee, USA, 7Department of Epidemiology, Tulane University School
of Public Health and Tropical Medicine, New Orleans, LA, USA, 8Beijing Institute of Ophthalmology, Beijing
Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital
Medical University, Beijing, China, 9National Center for Global Health and Medicine, Tokyo, Japan, 10Institute
of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, 11School of Chinese Medicine, China Medical
University, Taichung, Taiwan, 12Institute for Health Promotion, Graduate School of Public Health, Yonsei
University, Seoul, South Korea, 13Shanghai Diabetes Institute, Shanghai Jiaotong University Affiliated Sixth
People’s Hospital, Shanghai, China, 14Department of Epidemiology, School of Public Health and Jiangsu Key
Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow
University, Suzhou, China, 15Laboratory for Medical Science Mathematics, RIKEN Center for Integrative Medical
Sciences, Yokohama, Japan, 16Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, China, 17Genome
Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, 18Department of
Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating,
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
Hubei, China, 19Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA,
20Department of Ophthalmology, Taichung Veterans General Hospital, Taichung, Taiwan, 21Department of
Pediatrics, Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical
Center, Torrance, CA, USA, 22Division of Endocrinology and Metabolism, Department of Internal Medicine,
Taichung Veterans General Hospital, Taichung, Taiwan, 23School of Medicine, National Yang-Ming University,
Taipei, Taiwan, 24School of Medicine, National Defense Medical Center, Taipei, Taiwan, 25Institute of Medical
Technology, National Chung-Hsing University, Taichung, Taiwan, 26HudsonAlpha Institute for Biotechnology,
Huntsville, AL, USA, 27Department of Nutrition, Gillings School of Global Public Health, University of North
Carolina, Chapel Hill, North Carolina, USA, 28Singapore Eye Research Institute, Singapore National Eye Centre,
Singapore, Singapore, 29Duke-NUS Medical School Singapore, Singapore, Singapore, 30Department of
Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore,
31Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan, 32Division of
Endocrinology & Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei,
Taiwan, 33College of Medicine, National Taiwan University, Taipei, Taiwan, 34Institute of Preventive Medicine,
School of Public Health, National Taiwan University, Taipei, Taiwan, 35Carolina Population Center, University
of North Carolina, Chapel Hill, NC, USA, 36USC-Office of Population Studies Foundation, Inc, University of San
Carlos, Cebu City, Philippines, 37Department of Anthropology, Sociology, and History, University of San Carlos,
Cebu City, Philippines, 38Unit of Epidemiology, Hebrew University-Hadassah Braun School of Public Health,
1771Human Molecular Genetics, 2017, Vol. 26, No. 9 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/26/9/1770/3039197 by U
niversity of N
orth C
arolina at C
hapel H
ill user on 14 August 2019
Jerusalem, Israel, 39Department of Epidemiology and Population Genetics, Fuwai Hospital, Beijing, China,
40Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore,
41Khoo Teck Puat-National University Children’s Medical Institute, National University Health System,
Singapore, Singapore, 42Human Genetics Center, University of Texas School of Public Health, Houston, TX,
USA, 43Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital,
Taipei, Taiwan, 44Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan, 45Department of Biochemistry, National University of Singapore,
Singapore, Singapore, 46RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, 47School of
Medicine, Chung Shan Medical University, Taichung, Taiwan, 48Department of Medical Research, Taichung
Veterans General Hospital, Taichung, Taiwan, 49Department of Social Work, Tunghai University, Taichung,
Taiwan, 50Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan, 51Department of
Medicine, China Medical University, Taichung, Taiwan, 52Department of Medicine, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore, Singapore, 53Department of Functional Pathology,
Shimane University School of Medicine, Izumo, Japan, 54Department of Genetics, Shanghai-MOST Key
Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial
Technology Institute, Shanghai, China, 55NUS Graduate School for Integrative Science and Engineering,
National University of Singapore, Singapore, Singapore, 56Department of Statistics and Applied Probability,
National University of Singapore, Singapore, Singapore, 57Department of Medical Science Mathematics,
Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan, 58Beijing Tongren Eye Center,
Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Lab, Beijing Key Laboratory of
Intraocular Tumor Diagnosis and Treatment, Capital Medical University, Beijing, China, 59Department of
Epidemiology, Shanghai Cancer Institute, Shanghai, China, 60Department of Epidemiology, Graduate School of
Public Health, University of Pittsburgh, Pittsburgh, PA, USA, 61Division of Cancer Control and Population
Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 62Center for Public Health Genomics,
University of Virginia School of Medicine, Charlottesville, VA, USA, 63Center for Genome Science, Korean
National Institute of Health, Osong, Chungchungbuk-do, South Korea, 64Laboratory for Cardiovascular
Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, 65Department of Human Genetics
and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University,
Tokyo, Japan, 66Department of Biomedical Science, Hallym University, Chuncheon, South Korea,
67Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan and
68Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University of Heidelberg,
Mannheim, Germany
*To whom correspondence should be addressed. Tel: þ65 66015096; Fax: þ65 67791489; Email: ephsx@nus.edu.sg
Abstract
Large-scale meta-analyses of genome-wide association studies (GWAS) have identified>175 loci associated with fasting cho-
lesterol levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), and triglycerides (TG). With differences in linkage disequilibrium (LD) structure and allele frequencies between
ancestry groups, studies in additional large samples may detect new associations. We conducted staged GWAS meta-
analyses in up to 69,414 East Asian individuals from 24 studies with participants from Japan, the Philippines, Korea, China,
Singapore, and Taiwan. These meta-analyses identified (P<5108) three novel loci associated with HDL-C near CD163-
APOBEC1 (P¼7.4109), NCOA2 (P¼1.6108), and NID2-PTGDR (P¼4.2108), and one novel locus associated with TG near
WDR11-FGFR2 (P¼2.71010). Conditional analyses identified a second signal near CD163-APOBEC1. We then combined
results from the East Asian meta-analysis with association results from up to 187,365 European individuals from the Global
Lipids Genetics Consortium in a trans-ancestry meta-analysis. This analysis identified (log10Bayes Factor6.1) eight addi-
tional novel lipid loci. Among the twelve total loci identified, the index variants at eight loci have demonstrated at least nomi-
nal significance with other metabolic traits in prior studies, and two loci exhibited coincident eQTLs (P<1105) in subcuta-
neous adipose tissue for BPTF and PDGFC. Taken together, these analyses identified multiple novel lipid loci, providing new
potential therapeutic targets.
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Introduction
Cholesterol and triglyceride levels are modifiable risk factors for
cardiovascular diseases (CVD), a leading cause of death world-
wide (1). Genome-wide association studies (GWAS) have identi-
fied>175 loci associated with high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
total cholesterol (TC) and triglyceride levels (TG) (2–7). The larg-
est GWAS meta-analysis published to date has been performed
in populations predominantly of European ancestry (4). As lipid
profiles, allele frequencies, and environmental contributions
differ between populations, investigating genetic factors influ-
encing inter-individual variation in cholesterol and triglyceride
levels in non-European populations that have not been as
extensively studied can discover additional loci.
Several previous studies have investigated lipid trait associa-
tions in East Asian individuals (8–13). Novel loci near MYL2 and
HECTD2 were found to be associated with HDL-C in a GWAS meta-
analysis of more than 26,000 Korean individuals (9). A recent meta-
analysis conducted in 12,685 Chinese using an exome array identi-
fied missense variants associated with TG and LDL-C at PNPLA3
and PKD1L3, respectively (13). In addition, novel signals have been
identified in East Asians at previously established loci (11,13). For
example, rs2075291, encoding APOA5 Gly185Cys, is associated with
TG in East Asians (MAF¼ 0.06) (14), but not in>6,000 African
American or European individuals, likely due to a minor allele fre-
quency (MAF) that is rare (MAF<.005) in those populations (15).
Similarly, low-frequency (MAF<0.05) missense variants at CETP,
LDLR and PCSK9 were significantly associated with lipid traits in
Chinese, but non-polymorphic in other ancestries examined (13).
To date, the largest lipid genome-wide meta-analysis conducted in
East Asians was performed in 12,545 individuals with replication in
up to 30,395 (9).
In addition to examining studies with similar ancestry, com-
bining results across ancestries provides opportunities to
increase power to detect novel loci. For variant associations
shared across ancestry groups, the larger sample size obtained
by including studies from additional groups increases statistical
power compared to a single ancestry group. However, variants
may interact with environmental or other genetic factors that
disproportionately affect ancestry groups, generating differen-
ces in allelic effects across populations. While the fixed-effects
meta-analysis method assumes allelic effects to be the same
across ancestries, the Meta-ANalysis of TRans-ethnic
Association studies (MANTRA) algorithm allows for heterogene-
ity between more diverse ancestral populations (16). This
approach allows different allelic effect between populations,
and has successfully discovered many novel loci (15,17–23).
To identify additional loci, we meta-analyzed genome-wide
association data for HDL-C, LDL-C, TC and TG from up to 69,414
individuals of East Asian ancestry participating in the Asian
Genetic Epidemiology Network (AGEN). We also performed a trans-
ancestry meta-analysis combining the East Asian summary results
with publicly available summary results from 187,365 individuals
of European ancestry from the Global Lipids Genetic Consortium
(GLGC) (4). These analyses identified plausible candidate genes to
further elucidate cholesterol and triglyceride metabolism and iden-
tify possible new cholesterol management therapies.
Results
Study overview
To discover novel loci, we performed East Asian-specific meta-
analyses and East Asian-European trans-ancestry meta-
analyses with four lipid traits: HDL-C, LDL-C, TC, and TG. The
study design is described in Supplementary Material, Fig. S1.
The East Asian meta-analyses consisted of two phases. In the
first phase, we conducted a genome-wide discovery stage with
25,923 individuals in eleven studies from Japan, Korea, the
Philippines, China, Singapore, and Taiwan (Supplementary
Material, Tables S1 and S2) followed by in silico replication in up
to 26,676 individuals from five additional genome-wide studies.
Prioritized variants were then selected for de novo genotyping in
up to 19,936 individuals from five additional studies (see
Materials and Methods). In the second phase, we conducted a
second genome-wide meta-analysis by combining the original
discovery stage association results (eleven GWAS from Phase 1)
with 10,805 individuals from two new genome-wide studies
(BES and CHNS) that were not available during the first phase
discovery meta-analysis. Description of phenotype collection,
genotyping, and quality control metrics for each study are
shown in the Supplementary Materials and Tables S1 and S2.
We defined novel loci based on P< 5108 and a distance of at
least 1 Mb from the reported index variant at known loci. For
the trans-ancestry meta-analysis, we used MANTRA (16) to
meta-analyze association results from the larger, Phase 2 East
Asian meta-analysis with 187,365 individuals of European
ancestry from the GLGC (4), for a total of up to 221,739 individu-
als, and defined new loci based on log10 Bayes factor (BF) 6.1,
requiring nominal significance (fixed effects P< 0.05) in each
ancestry alone. Finally, we examined association evidence for
all apparently novel loci in 10,857 individuals from four addi-
tional East Asian studies (MESA, TaiChi, TaiChi-G, and TUDR).
All East Asian-specific analyses were performed with and
without adjustment for body mass index (BMI). Results from
both models were largely similar, with the BMI-adjusted models
exhibiting stronger P-values and slightly larger beta estimates
(Supplementary Material, Table S3 and S4, Figs S2 and S3). For
the East Asian analyses, we present results from the BMI-
adjusted models. Sensitivity analyses were performed by
excluding non-fasting samples. As there were no appreciable
differences, we report results including non-fasting samples for
maximal sample size. In the trans-ancestry meta-analysis, we
present results from the BMI-unadjusted model based on data
availability from GLGC.
Four novel lipid loci identified through East Asian
meta-analysis
In the discovery stage from the first phase of the East Asian
meta-analysis, we identified 25 previously known loci associ-
ated (P< 5108) with one or more lipid traits (Supplementary
Material, Tables S3 and S4, Figs S2 and S3). Based on the discov-
ery stage, we selected 3,870 variants with P< 1103 and pair-
wise LD r2< 0.1 to evaluate in the in silico stage. After meta-
analysis of the discovery and in silico stages, we selected 36 var-
iants for de novo genotyping (see Materials and Methods). Meta-
analyses of the three stages (totaling 21 studies, up to 69,414
subjects) identified ten additional previously known lipid loci
(Supplementary Material, Table S5). We identified one novel
locus associated with TG (rs10886863, near WDR11 and FGFR2,
PadjBMI¼2.73  1010) and two novel loci associated with HDL-C
(rs10504476, near NCOA2, PadjBMI¼1.62  108; rs10144765, near
NID2 and PTGDR, PadjBMI¼4.16  108) (Table 1, Fig. 1,
Supplementary Material, Table S6). In this first phase of East
Asian analysis, we also observed that two loci previously
reported to be associated with one lipid trait are now associated
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with an additional trait, including rs2792751 (near GPAM, HDL-
C, PadjBMI¼2.21  1010), and rs1230180 (near METAP1 and ADH5,
TC, PadjBMI¼4.63  108) (Supplementary Material, Table S6). In
the second phase of the East Asian meta-analysis, we replicated
additional established loci (Supplementary Material, Table S7),
and identified a third novel HDL-C association near CD163 and
APOBEC1 (rs10743940, PadjBMI¼2.30  109) (Table 1, Fig. 1). Forest
plots for the four novel loci are presented in Supplementary
Material, Fig. S4A and B. All four novel loci were validated to
have the same direction of effect in up to an additional 10,857
Figure 1. Regional association plots of the four loci identified from East Asian meta-analysis. (A) WDR11-FGFR2, (B) NID2-PTGDR, (C) CD163-APOBEC1, (D) NCOA2. –log10 (P-val-
ues) are plotted against the hg19 genomic coordinates at each locus. The purple circle represents the lead variant, which exhibited the strongest evidence of association at
the locus among HapMap-imputed variants. Variants are colored based on 1000 Genomes Project Phase 3 East Asian LD with the lead variant. Results shown in A,B, and D
are from Phase 1 of the East Asian meta-analysis, while C is from Phase 2 of the East Asian meta-analysis. Stage 1 indicates the Phase 1 discovery stage results, 1þ 2 indi-
cates the results after the in silico stage, and 1þ2þ3 indicates the results after the de novo genotyping stage.
Table 1. New associations with lipid traits identified in the East Asian meta-analysis (P< 5 108)
Trait Variant Chr Position Locus N EA/NEA EAF Adjusted for age, sex Adjusted for age, sex, BMI
Beta SE P-value Phet Beta SE P-value Phet
TG rs10886863 10 122,929,493 WDR11-FGFR2 45,245 C/T 0.64 0.041 0.007 2.71  108 0.275 0.041 0.006 2.73  1010 0.175
HDL-C rs10743940 12 7,651,138 CD163-APOBEC1 34,243 A/T 0.30 0.050 0.009 7.00  109 0.105 0.050 0.008 2.30  109 0.163
HDL-C rs10504476 8 71,267,629 NCOA2 42,731 G/A 0.60 0.040 0.007 2.11  107 0.993 0.042 0.007 1.62  108 0.812
HDL-C rs10144765 14 52,559,930 NID2-PTDGR 54,176 G/C 0.27 0.031 0.007 1.63  106 0.626 0.035 0.007 4.16  108 0.380
East Asian meta-analysis results from Phases 1 and 2 (without and with adjustment for BMI). Genome-wide significant association is defined as P<5108. Physical
positions based on hg19. Effect alleles are associated with higher triglyceride and HDL-C trait values. Beta estimates reflect per allele effects of variants on inverse nor-
mal transformed traits. rs10743940 at CD163-APOBEC1 attained genome-wide significance at Phase 2 (N up to 34,421). The other three loci attained genome-wide signifi-
cance from combined analysis of Phase 1 discovery, in silico, and de novo stages (N up to 61,607 for HDL-C, and N up to 45,839 for TG).
Chr, chromosome; EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; SE, standard error; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
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individuals from four additional East Asian studies
(Supplementary Material, Table S8).
To explore the presence of multiple signals at novel lipid-
associated loci, we performed approximate conditional analyses
at the WDR11-FGFR2, CD163-APOBEC1, NCOA2, and NID2-PTGDR
loci using Genome-wide Complex Trait Analysis (GCTA) (24)
within a 500 kb window upstream and downstream of the index
variant. The only evidence of a second signal was identified at
the CD163-APOBEC1 locus (rs1419980; Pinitial¼3.7  108;
Pjoint¼3.9  106), approximately 123 kb downstream of the first
signal (rs10743940) (Fig. 2A). The LD between the two variants
computed using 1000 Genomes Phase 3 East Asians is r2¼0.02
and D’¼0.16, suggesting the two signals are essentially inde-
pendent from one another.
Trans-ancestry meta-analysis
In the trans-ancestry analysis of up to 222,739 East Asian and
European samples, we validated 151 established lipid loci at
log10BF 6.1 (Supplementary Material, Table S9). We further
replicated two loci (LOC100996634 and CTC1-PFAS) recently
reported in similar meta-analysis of>4,700 Mexican individuals
with the GLGC European samples (23) (Supplementary Material,
Table S10). We also observed 10 novel loci associated with one
or more of the four lipid traits (five with HDL-C, three with TG,
one with LDL-C, and one with TC) and one locus associated with
both LDL-C and TC (Table 2). All of the lead variants showed
moderate evidence of association in the Europeans (fixed effect
P-values 5.30  104 to 6.42  108) and demonstrated at least
nominal association (fixed effect P-values 0.048 to 2.06  108)
in the East Asians. The lead variants at all novel loci are com-
mon (MAF> 0.05 in East Asians and Europeans). The loci with
the strongest evidence of an association were observed with
variants near CD163-APOBEC1 (log10BF¼ 8.14, HDL-C), SNTB1
(log10BF¼ 7.48, HDL-C), BPTF (log10BF¼ 7.88, TG), and GPR180
(log10BF¼ 7.36, TG). We present fixed-effect meta-analysis
results in each ancestry for comparison. The fixed-effect meta-
analysis P-values were significant at only six of the ten loci,
with comparable allelic sizes across the East Asians and
Europeans.
Two of the novel loci identified in the East Asian HDL-C
meta-analyses, CD163-APOBEC1 and NCOA2, were also
Figure 2. HDL-C locus CD163-APOBEC1 exhibits two signals. (A) The two signals, rs10743940 and rs1419980, identified in Phase 2 of the East Asian meta-analysis, shown
with the log10BF on the y-axis. (B) log10BF results from the GLGC European data showing the variant associations at the locus. (C) Trans-ancestry meta-analysis.
Variants are colored based on LD with the lead variants, rs10743940 (red) and rs1419980 (blue) based on 1000 Genomes Project Phase 3 East Asian (A) and European
(B and C) LD. (D) Fixed effect association results at two lead variants (rs10743940 and rs1419980) in East Asians and Europeans. Pinitial is the P value result from the
unconditioned analysis. Pconditional is the joint conditional P value for each variant after conditioning on the other variant. (E) Haplotypes of rs10743940 and rs1419980
in the China Health and Nutrition Survey data. Alleles associated with lower HDL-C are shown in purple while alleles associated with higher HDL-C are shown in green.
Haplotype association was performed with HDL-C inverse normalized residuals after adjusting for age, age2, sex, and BMI from the China Health and Nutrition Survey
study using the most frequent haplotype as the reference.
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identified in the trans-ancestry analyses with different lead var-
iants (Table 2). The LD between the lead variants of NCOA2
(rs10504476 and rs6982451, East Asian LD r2¼0.79) suggests the
East Asian and trans-ancestry-identified variants are both part
of the same signal. However, at CD163-APOBEC1, the lead East
Asian variant is not in LD with the lead trans-ancestry-
identified variant (rs10743940 and rs1419980, East Asian LD
r2¼0.02). Instead, the lead trans-ancestry variant is the lead var-
iant for the second signal at this locus in the East Asian analysis
after conditional analysis on the first signal. The locus associa-
tion plots in East Asians, Europeans, and the trans-ancestry
analyses (Fig. 2A–C) suggest that the first signal at CD163-
APOBEC1 (lead variant: rs10743940) may be East-Asian-specific
(MAF¼ 0.30), and the second signal (lead variant: rs1419980) is
shared between the Europeans and East Asians. The allele fre-
quency of rs1419980 is higher in the East Asians (MAF¼ 0.32)
compared to Europeans (MAF¼ 0.07) and reached significance in
East Asians (PadjBMI¼1.9108; PunadjBMI¼5.4108). No evidence
of association was observed at rs10743940 in 94,169 Europeans
(MAF¼ 0.03; P¼ 0.17), and European LD between the two lead
variants was 0.02. The strongest association at this locus in
Europeans was at rs7132326 near the second signal (MAF¼ 0.05;
log10BF¼ 2.62; P¼ 9.92  105; European LD r2¼0.03 and 0.66
with rs10743940 and rs1419980 respectively) (Fig. 2B). Among
the ten loci and using a Bonferroni threshold (P< 0.05/
10¼ 0.005), only CD163-APOBEC1 exhibited evidence of heteroge-
neity (Phet¼0.003), possibly due to the presence of the second
signal in East Asians.
The remaining two novel signals identified in the East Asian
meta-analysis near WDR11-FGFR2 (rs10886863: log10BF¼ 2.17;
fixed-effect P-value¼ 2.23  103) and NID2-PTDGR (rs10144765:
log10BF¼ 2.77; fixed-effect P-value¼ 1.60  103) were not signif-
icant in the trans-ancestry meta-analysis. Allele frequencies of
the East Asian lead variants were notably lower in Europeans,
and no evidence of association was observed in GLGC at either
variant despite being well-powered to detect the association
(rs10886863: MAF¼ 0.03, P¼ 0.13; rs10144765: MAF¼ 0.03,
P¼ 0.21) (Supplementary Material, Table S11).
In addition to the trans-ancestry analysis of lipid traits
unadjusted for BMI, we performed a sensitivity analysis by
meta-analyzing the BMI-adjusted results from the East Asian
meta-analysis with the BMI-unadjusted European results
(Supplementary Material, Table S12). We identified nine loci
that were also observed in the BMI-unadjusted analysis,
although the index variant was different at one of the loci. Two
additional loci were identified in the BMI-adjusted analysis.
However, two loci identified in the original analysis were not
found in the BMI-adjusted analysis.
Biological annotations
We investigated multiple resources to identify candidate genes
at each of the novel loci from the East Asian and trans-ancestry
meta-analyses (Table 3). Nonsynonymous variants in high LD
(European and East Asian r2> 0.80) with an index variant exist
at two loci: the first (East Asian) signal at CD163-APOBEC1
(CD163, I324V) and the locus near ADPGK (BBS4, I182T). We
examined eQTLs in blood, liver, and adipose and found two loci
coincident (r2> 0.80 in both East Asians and Europeans) with
eQTLs in subcutaneous adipose (Table 3, Supplementary
Material, Table S13). At eight loci, the index variants associated
with a lipid trait showed at least nominal evidence of associa-
tion in GWAS for other metabolic traits (SupplementaryT
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Material, Table S13). For example, the index variant at PDGFC,
associated with HDL-C, is also nominally associated with type 2
diabetes and four glycemic traits, and the variant at WDR11-
FGFR2, associated with TG, is also associated with adiponectin
levels (P¼ 4.4  109) in East Asians. Seven traits across five
genes met a multiple testing p-value threshold of 0.0033 (15 var-
iants). In a manual literature search, we identified at least 1
potential candidate gene at nine loci (Table 3, Supplementary
Material).
Discussion
This study represents the largest GWAS meta-analysis per-
formed for cholesterol and triglyceride associations with indi-
viduals of East Asian ancestry to date. The two-phase East
Asian meta-analysis identified three novel loci associated with
HDL-C and one novel locus associated with TG. At one of the
novel HDL-C loci, CD163-APOBEC1, we identified two signals,
one of which is shared with Europeans. We also conducted a
trans-ancestry meta-analysis of East Asians and Europeans
identifying 10 novel loci associated with HDL-C, LDL-C, TC, and
TG. Several of the identified loci harbor candidate genes based
on eQTLs and literature review.
Despite prior studies with sample sizes of nearly 200,000
European individuals, four loci were identified in the East Asian
meta-analysis that have not been described previously. In the
European data, these lead variants were not nominally signifi-
cant (all P> 0.13; Supplementary Material, Table S14). The loci at
WDR11-FGFR2, NID2-PTDGR, NCOA2, and CD163-APOBEC1 may
have been identified in East Asians because their allele frequen-
cies are higher (MAF 0.27–0.40) compared to Europeans (MAF
0.03–0.13). The higher frequency among East Asians allowed us
to detect these associations in a smaller sample size.
As expected, the trans-ancestry meta-analysis replicated
most (151 of the 157) loci reported in the European data alone.
Of the loci that did not replicate, most exhibited opposite direc-
tion of effects between East Asians and Europeans (ASAP3,
ADH5, AMPD3, and FTO) (Supplementary Material, Table S9).
Meta-analysis association results from multiple ancestries pro-
vide an opportunity to increase the overall power to detect
novel loci (15,17–22). For all ten loci identified here, the P-values
in the European samples were suggestive (P< 1106), and the
increase in sample size from the addition of the East Asians
allowed these loci to be considered significant.
Our data suggested two essentially independent signals are
present at the novel HDL-C locus, CD163-APOBEC1. The lead var-
iant of the first signal, rs10743940, is located within an intron of
CD163. The lead variant of the second signal, rs1419980, is
located 124 kb downstream of the first signal, 71 kb from the 5’
end of CD163 and 27 kb from the 3’ end of APOBEC1. Both var-
iants were significant in the East Asian meta-analysis, and the
joint conditional P-value for both variants reached locus-wide
significance (P< 1105) at Pjoint¼ 4  106. The lead variant at
the second signal is also the lead variant that arose from the
trans-ancestry meta-analysis, suggesting the second signal is
shared between Europeans and East Asians. Of note, the
European lead variant in the GLGC dataset, rs7132326, is in
moderate LD (European LD r2¼0.66) with the lead variant of the
second (shared) signal, rs1419980. While the first signal lies
within CD163, a gene that encodes the CD163 hemoglobin scav-
enger receptor protein, the nearby gene, APOBEC1
(Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 1), is
an excellent candidate gene for both signals. APOBEC1 is known
to play a role in cholesterol control and metabolism, asT
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knockout of the Apobec1 gene in mice resulted in a significant
decrease in HDL-C levels (25,26). While we were able to detect
two separate signals at this locus, these variants may still by
partially tagged by a different variant not present in the
HapMap reference panel. Larger sample sizes and dense impu-
tation reference panels are needed to further characterize this
locus.
At the novel TG-associated locus WDR11-FGFR2, nearby var-
iants have previously been associated with adiponectin levels
in East Asians (27). The lead variant for the adiponectin signal
(rs3943077; P¼ 3.01014) is located 15 kb from the lead TG-
associated variant rs10886863, and the two variants exhibit
weak LD (East Asian r2¼0.23, D’¼0.85). The lead variant alleles
associated with lower TG levels are associated with higher adi-
ponectin levels. The variants are located within a predicted
enhancer region based on chromatin marks (28) 260 kb from the
3’ end of WDR11 and 308 kb from the 3’ end of FGFR2. FGFR2 enc-
odes the fibroblast growth factor receptor 2 and is known to
play a role in lipogenesis (29). FGFR2 is also highly expressed in
adipose tissue where triglycerides are stored (30), suggesting
FGFR2 as a better candidate gene at this locus. Another TG-
associated locus, ADPGK, is located approximately 50kb down-
stream of BBS4, which has also been shown to play a role in the
TG accumulation in adipocytes (31).
At least three additional loci discovered in our analysis har-
bor genes known to play roles in lipid metabolism. NCOA2
(nuclear receptor coactivator 2) is a member of the nuclear hor-
mone receptor coactivator family (32) and is known to play
an important role in both adipogenesis and lipid metabolism
(33–36). Mice with a complete knockout of Ncoa2 demonstrated
increased energy expenditure, an inability to store fat in the adi-
pocytes, and an inability to absorb dietary fat from the gut (33).
The mice also have significantly decreased levels of key regula-
tory enzymes required for fatty acid and cholesterol biosynthe-
sis (35). Two variants within NCOA2 were recently reported to
be nominally associated (P< 0.05) with obesity and dyslipidemia
in 529 Chinese individuals (37). At another locus, SNTB1 encodes
syntrophin beta 1, which interacts with ABCA1 (ATP-binding
cassette transporter A1), a major regulator of cellular HDL-C
(38). Additionally, rs4871137 was recently reported as a novel
pleiotropic locus for lipids and inflammation (39). Finally, four
hundred kb upstream of the BPTF locus, PITPNC1 encodes a
phosphatidylinositol transfer protein and is known to have play
several roles in lipid metabolism including the binding and
transferring of phosphatidic acid (40), regulating the synthesis
of phosphinositides (41), cellular distribution and metabolism of
lipids (42).
G-protein coupled receptors (GPCR) are commonly used as
therapeutic targets, particularly in the treatment of dyslipide-
mia (43). In our meta-analyses, we identified three loci at or
near four genes known to encode GPCRs (GPR180, S1PR4, PTGDR,
and PTDGER2). At the TG-associated locus, GPR180 encodes a
GPCR in the rhodopsin family with a suggested role in vascular
remodeling (44). S1PR4, an HDL-C-associated locus, encodes a
sphingosine-1-phosphate receptor that binds lysophospholipids
or lysphingolipids and is involved in endothelial differentiation
(45). Finally, PTGD and PTGER are located approximately 174 kb
downstream and 221 kb downstream, respectively, of HDL-
associated variant rs10144765. PTGDR and PTGER2 encode the
prostaglandin D2 and E2 receptors that are members of the gua-
nine nucleotide-binding GPCR superfamily and mediate allergic
and airway inflammation (46). Previously, this family of GPCRs
has been used as a therapeutic target for coronary artery dis-
ease and atherosclerosis (47).
In conclusion, our East Asian GWAS meta-analysis for HDL-
C, LDL-C, TC, and TG provides evidence for novel HDL-C loci
near CD163-APOBEC1, PTGDR, and NCOA2, and a new TG locus
near WDR11-FGFR2. The trans-ancestry meta-analysis also pro-
vides evidence for eight additional novel loci, including several
with previously undiscovered roles in lipid biology. Additional
loci will likely be discovered with the use of more dense refer-
ence panels, larger sample sizes, and larger trans-ancestry
meta-analyses, further expanding our understanding of the
genetic basis of cholesterol and triglyceride levels.
Materials and Methods
Study populations
The East Asian meta-analyses were performed with studies par-
ticipating in the Asian Genetic Epidemiology Network (AGEN), a
consortium of genetic epidemiology studies of type 2 diabetes
and related traits conducted in individuals of East Asian ances-
try (see URLs, Supplementary Methods). The first phase of the
East Asian meta-analysis involved a three-stage design: i) meta-
analysis of genome-wide association results of up to 25,164
Chinese, Japanese, Filipino, Korean, and Malay individuals from
eleven GWAS (Phase 1 discovery); ii) in silico replication in five
independent studies of up to 26,676 Japanese, Chinese, and
Korean individuals (Phase 1 in silico), and iii) further de novo gen-
otyping in up to 19,936 Japanese, Chinese, and Korean individu-
als from five additional studies (Phase 1 de novo)
(Supplementary Material, Fig. S1 and Table S1). In Phase 2 of the
East Asian analysis, we meta-analyzed the Phase 1 discovery
data with newly available GWAS data from two additional stud-
ies with 10,805 Chinese individuals (BES and CHNS; combined
n 34,421). Both phases of East Asian meta-analyses included
21 population-based and five case-control studies with a total of
69,414 individuals. In the trans-ancestry meta-analysis, we
meta-analyzed the results from the larger, Phase 2 of the East
Asian meta-analysis with the publicly available summary
results for up to 187,365 individuals of European ancestry from
the Global Lipids Genetic Consortium (GLGC) (4), for a combined
total of up to 221,585 individuals. The lead variant at each novel
locus identified from the East Asian and trans-ancestry meta-
analyses was then evaluated in four independent studies of up
to 10,886 East Asian individuals (MESA, TaiChi, TaiChi-G, and
TUDR). Institutional review boards approved all study protocols
at their respective sites, and written informed consent was
obtained from all participants.
Genotyping, imputation, and quality control
Studies included in East Asian genome-wide discovery, and in
silico replication were genotyped using commercially available
Affymetrix or Illumina genome-wide genotyping arrays. Quality
control criteria implemented in each study, including variant
call rate and Hardy-Weinberg equilibrium (HWE), were sum-
marized in Supplementary Material, Table S2. We present prin-
cipal component plots with either HapMap or 1000 Genomes
Project for a subset of the studies, representing each of the
major East Asian populations from China, Japan Korea,
Philippines, and Singapore (Supplementary Material, Fig. S6). All
studies performed genotype imputation to HapMap Project
Phase II reference panel (JPTþCHB for all studies except CLHNS,
which used JPTþCHBþCEU, and SiMES, which used
JPTþCHBþCEUþYRI) of 2.4 million variants using Beagle (48),
IMPUTE (49), or MACH (50). The two newly available GWAS,
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CHNS and BES, were imputed to the 1000 Genomes Project
Phase 3 reference panel (51) using the University of Michigan
imputation server (52). Only variants included in the HapMap
reference panel were included in the meta-analyses. Variants
with poor imputation quality (IMPUTE or BEAGLE quality score-
< 0.50 or MACH r2< 0.30) or with a minor allele frequency< 5%
were excluded from the association analyses. De novo genotyp-
ing for variants that showed compelling evidence of association
from the Phase 1 discovery and in silico meta-analysis was per-
formed in five additional studies using the Sequenom
MassARRAY iPLEX system or TaqMan assays (Supplementary
Material, Table S1). All reported European and East Asian LD
information was calculated based on the 1000 Genomes Phase 3
reference panel using LDLink. East Asian and European minor
allele frequencies were drawn from the East Asian Phase 2 and
GLGC respectively.
Phenotype measurements
Plasma blood lipid levels were measured by standard biochemi-
cal methods in mg/dl. Studies with fasting blood lipids contrib-
uted data to all four lipid analyses, while non-fasting studies
contributed to the HDL-C and TC analyses only. If both fasting
and non-fasting samples were available, analyses were per-
formed separately for fasting and non-fasting samples. Directly
measured LDL-C levels were used when available; otherwise,
we estimated LDL-C using Friedewald formula only on fasting
samples: if TG400 mg/dl, LDL-C¼TC – HDL-C – (TG/5); if
TG> 400, LDL-C values were set to missing (53). Individuals on
lipid lowering medications were excluded from all analyses.
Statistical analysis and variant prioritization
Association analyses within each cohort. In each individual study,
residuals for each lipid trait were computed by including age,
age2, sex, and other study-specific covariates (e.g. principal
components, sample recruitment sites) in a linear regression
model (Supplementary Material, Table S2). In a second model,
BMI was included as an additional covariate. The residuals were
then inverse-normalized to approximate a normal distribution
with a mean value of 0 and standard deviation of 1. For studies
ascertained based on case or control status, trait transformation
was computed in cases and controls separately. Linear regres-
sion models assuming an additive mode of inheritance were
applied to test for genotype-phenotype association with nor-
malized residuals.
East Asian phase 1 and 2 GWAS discovery meta-analyses. The
meta-analyses for associations between the four lipid traits
with 2.4 million variants were performed by two independent
analysts, each using Stouffer sample-size weighted fixed effects
meta-analysis implemented in METAL (54). We used a fixed
effects meta-analysis as this approach assumes the same
underlying allelic effects on disease susceptibility and is more
appropriate among homogeneous studies from the same ances-
try (16). Study-specific summary statistics were corrected using
genomic-control (kGCranges 0.989 – 1.102) prior to meta-
analysis; overall meta-analysis results were also corrected for
genomic control (Supplementary Material, Table S1). Cochran’s
Q-test was used to assess for the presence of heterogeneity. We
obtained effect sizes by performing an inverse-variance
weighted meta-analysis on study-specific inverse normal trans-
formed trait values. The same protocol was used in the second
phase of the East Asian meta-analysis where the eleven Phase 1
discovery studies were combined with two newly available
cohorts (BES and CHNS).
East Asian Phase 1 in silico replication. We selected 3,870 variants
with P-value< 1  103 in either model (with and without BMI
adjustment) from the Phase 1 discovery meta-analysis to
follow-up in 26,676 individuals from five GWAS studies. The P-
value threshold was determined from visually observing the
quantile-quantile (Q-Q) plots for each trait after excluding
known loci (Supplementary Material, Fig. S2). For uniformity, we
applied the same threshold to all four lipid traits. To prioritize
variants for in silico replication, we used the ‘-clump’ command
in PLINK (55) using the HapMap CHBþ JPT as reference, and set-
ting an East Asian LD threshold r2< 0.10 and a physical distance
of 1 Mb. We then meta-analyzed study summary statistics from
the in silico replication with the data from the eleven studies in
Phase 1.
East Asian phase 1 de novo genotyping. For the 79 lead variants
that showed suggestive evidence of association (P< 5  106) in
the East Asian Phase 1 discovery and in silico meta-analysis, we
compared the physical locations to known index variants col-
lected from literature (2,4,9) and considered variants to be at an
established locus if they were located within 1 Mb and/or in LD
(r2 0.1 using HapMap JPTþCHB) of a reported index variant. To
prioritize variants for de novo genotyping, we grouped variants
into six tiers: (1) variants at loci not previously reported to be
associated with any of the four lipid traits; (2) variants at loci
previously reported to be associated with a different lipid trait;
(3) variants at previously known loci, but in low LD (r2< 0.10)
with the published index variant(s); (4) variants at previously
known loci and in LD (r2 0.10) with an index variant identified
in a study of European participants; (5) variants at loci discov-
ered (P< 5108) after meta-analysis of the discovery and in sil-
ico stages; (6) or variants in the Major Histocompatibility
Complex (MHC) region. When multiple variants at a locus met
these tiers, variants with larger discovery sample sizes or
known variant consequences were selected. Constrained by
resources and the capacity of de novo genotyping, the top 36 var-
iants (27 from Tier 1, 5 from Tier 2, and 4 from Tier 3) were
selected for de novo genotyping in 19,936 individuals from five
studies. We combined study-level summary statistics from the
Phase 1 discovery, in silico, and de novo stages in a joint meta-
analysis.
Trans-ancestry meta-analysis
For the trans-ancestry meta-analysis, we meta-analyzed the
larger East Asian Phase 2 genome-wide summary statistics
(n 34,421) with European summary statistics from GLGC using
the Meta-ANalysis of Trans-ethnic Association Studies
(MANTRA) software (16). We defined log10BF 6.1 as genome-
wide significant, approximately comparable to P< 5  108 (56).
Conditional analysis
To test for multiple signals at the four novel loci identified in
the East Asian meta-analysis, we carried out approximate con-
ditional analysis using summary level association statistics as
implemented in Genome-Wide Complex Trait (GCTA) program
(24). We used allele frequency and LD estimates from the largest
Chinese study, CHNS, to approximate the reference variance-
covariance matrix of genotypes. Analyses were also conducted
using the SCES study to approximate the reference variance-
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covariance genotype matrix; results were similar (data not
shown).
Further evaluation in four additional East Asian studies
Four additional East Asian cohorts became available for further
examination of the novel loci: MESA, TaiChi, TaiChi-G, and
TUDR (Supplementary Material, Table S2). Each study provided
BMI-adjusted or BMI-unadjusted results for the index variant at
each novel locus that exhibited significant results in either the
East Asian or trans-ancestry meta-analyses. Results for up to
10,857 individuals were available after meta-analysis
(Supplementary Material, Table S8).
Associations with other metabolic traits and outcomes
We used the Type 2 Diabetes Knowledge Portal (57) to explore
associations of the newly identified loci with other metabolic
traits and outcomes. Association summary statistics from the
following consortia: coronary artery disease from CARDIoGRAM
(58), kidney-related traits from CKDGen (59), type 2 diabetes
from DIAGRAM (60), BMI and waist-to-hip ratio from GIANT
(61,62), and glycemic traits from MAGIC (63–66) were available
for query on the portal (last assessed August 8, 2016).
Additionally, we used available data from AGEN East Asian adi-
ponectin (27) and ICBP-GWAS (systolic and diastolic blood pres-
sure) (67). Effect sizes for each data set were obtained from
publicly available summary statistic files.
Exploration of expression quantitative trait loci (eQTL) at
novel loci
We searched publicly available eQTL databases, GTEx (68,69),
the Blood eQTL Browser (70), and the University of Chicago
eQTL browser (71) to identify cis-eQTLs at the observed loci in
blood, liver, and adipose tissue. We also searched for cis-eQTLs
in subcutaneous adipose tissue data from the METSIM study
(72). Coincident eQTLs were identified in the METSIM data if the
lead eSNP and the GWAS index variant were in high LD (r2>0.80)
in both Europeans and East Asians to accommodate the eQTL
source and the European ancestry composition of the trans-
ancestry data. Reciprocal conditional analyses were also per-
formed using the METSIM data to determine if the GWAS index
variant and the lead eSNP were part of the same eQTL signal.
Determining the most biologically relevant gene(s) at
each novel locus
We used SNIPPER (see URLs) to identify nearby genes 500 kb
upstream or downstream of the index variant at each of the
novel loci. SNIPPER returns information about each gene from
NCBI Entrez Gene, Gene Ontology terms, KEGG pathways, and
PubMed. We included the following keywords as search terms
for PubMed: lipid, cholesterol, triglyceride, and metabolic. After
analyzing results from SNIPPER, we then conducted an addi-
tional traditional literature review through PubMed and OMIM
to identify candidate genes. A gene was considered a potential
candidate if there was an apparent link to lipid biology, based
on prior studies of that particular gene.
Web Resources
Summary statistics for the East Asian meta-analyses are avail-
able at:
https://blog.nus.edu.sg/agen/summary-statistics/
AGEN, http://blog.nus.edu.sg/agen/
IMPUTE, http://mathgen.stats.ox.ac.uk/impute/impute_v2.
html
MACH, http://www.sph.umich.edu/csg/abecasis/MACH/inde
x.html
Beagle, http://faculty.washington.edu/browning/beagle/bea
gle.html
University of Michigan Imputation Server, https://imputa
tionserver.sph.umich.edu/index.html
SNPTEST, https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.html
PLINK, https://www.cog-genomics.org/plink2
ProbABEL, http://www.genabel.org/
GCTA, http://cnsgenomics.com/software/gcta/
SAS, http://www.sas.com/software/sas9/
R, http://www.r-project.org/
LDLink, http://analysistools.nci.nih.gov/LDlink/
Type 2 Diabetes Knowledge Portal, http://www.type2diabe
tesgenetics.org/
ICBP-GWAS data, http://locuszoom.sph.umich.edu/locuszoom/
GTEx, http://www.gtexportal.org/home/
Blood eQTL Browser, http://genenetwork.nl/bloodeqtlbrow
ser/
University of Chicago eQTL Browser, http://eqtl.uchicago.
edu/cgi-bin/gbrowse/eqtl/
HaploReg, http://www.broadinstitute.org/mammals/hap
loreg/haploreg.php
SNIPPER, http://csg.sph.umich.edu/boehnke/snipper
NCBI Entrez Gene, http://www.ncbi.nlm.nih.gov/gene
Gene Ontology, http://geneontology.org/
KEGG Pathways, http://www.genome.jp/kegg/pathway.html
PubMed, http://www.ncbi.nlm.nih.gov/pubmed
OMIM, http://www.ncbi.nlm.nih.gov/omim
All URLs were last accessed on March 1, 2017.
Supplementary Material
Supplementary Material is available at HMG online.
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